(Q33737479)

29 July 2017

0 references

A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis (English)

1 reference

29 July 2017

aggressive fibromatosis

1 reference

1 reference

Jean-Emmanuel Kurtz

1

1 reference

29 July 2017

Irène Asmane

2

1 reference

29 July 2017

Anne-Claire Voegeli

3

1 reference

29 July 2017

Agnès Neuville

4

1 reference

29 July 2017

Armelle Dufresne

5

1 reference

29 July 2017

Valère Litique

6

1 reference

29 July 2017

Christine Chevreau

7

1 reference

29 July 2017

Jean-Pierre Bergerat

8

1 reference

29 July 2017

17 March 2010

1 reference

29 July 2017

1 reference

29 July 2017

2010

1 reference

29 July 2017

458156

1 reference

Creative Commons Attribution 3.0 Unported

29 July 2017

start time

1 January 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841250

Imatinib in the treatment of solid tumours

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841250

A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841250

Recent advances in the understanding of mastocytosis: the role of KIT mutations.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841250

Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841250

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841250

The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841250

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841250

Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841250

KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841250

Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder.

21 June 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F458156

Response of extraabdominal desmoid tumors to therapy with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F458156

A novel KIT missense mutation in one Chinese family with piebaldism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F458156

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F458156

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F458156

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F458156

Re: Response of a KIT-Positive Extra-abdominal Fibromatosis to Imatinib Mesylate and KIT Genetic Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F458156

c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia

21 January 2018

1 reference

12 December 2020

Desmoid-type fibromatosis

1 reference

12 December 2020

Desmoid-type fibromatoses involving the brachial plexus: treatment options and assessment of c-KIT mutational status

1 reference

12 December 2020

Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis

1 reference

12 December 2020

Identifiers

DOI

10.1155/2010/458156

1 reference

29 July 2017

1 reference

29 July 2017

1 reference